Gastric/GEJ Cancer
Showing 1 - 25 of >10,000
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Tucson (Tadalafil 20 MG)
Not yet recruiting
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Tadalafil 20 MG
-
Tucson, ArizonaArizona Cancer Center at UMC North/University Medical Center
Feb 1, 2023
Gastric Cancer Trial in Tianjin (AK104, Apatinib, Paclitaxel)
Recruiting
- Gastric Cancer
- AK104
- +3 more
-
Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
May 7, 2023
Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer Trial (T-Dxd(Trastuzmab deruxtecan), Ramucirumab)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal Junction (GEJ) Cancer
- T-Dxd(Trastuzmab deruxtecan), Ramucirumab
- (no location specified)
Jun 7, 2023
Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer Trial (TST001, CapOx or mFOLFOX6 and NIVO or (Substudy)
Not yet recruiting
- Gastric Cancer
- +2 more
- TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
- Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
- (no location specified)
Oct 16, 2023
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric
Available
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer
- +3 more
-
Morristown, New JerseyAMG Hematology/Oncology
Sep 15, 2023
Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer Trial (LB1908)
Not yet recruiting
- Gastric Cancer
- +3 more
- LB1908
- (no location specified)
Sep 9, 2022
Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1
Active, not recruiting
- Gastric or Gastroesophageal Junction Adenocarcinoma
- neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Hospital
Jul 4, 2023
Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)
Not yet recruiting
- Adenocarcinoma - GEJ
- Gastric Adenocarcinoma
- (no location specified)
Sep 26, 2023
Gastric Cancer, Peritoneal Metastases, Ascites, Malignant Trial in Hangzhou (Sintilimab in Combination With S-1/oxaliplatin With
Recruiting
- Gastric Cancer
- +2 more
- Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion
- Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Sep 18, 2023
Stomach Tumors, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Atezolizumab, Tiragolumab, Oxaliplatin)
Active, not recruiting
- Stomach Neoplasms
- +2 more
- Atezolizumab
- +3 more
-
Beijing, China
- +10 more
Dec 21, 2022
Adenocarcinoma, Stomach Tumor, Gastroesophageal-junction Cancer Trial in Shanghai (radiation, biological, drug, procedure)
Recruiting
- Adenocarcinoma
- +8 more
- Radiotherapy targeted to the primary lesion
- +7 more
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Nov 7, 2023
PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer Trial in Changchun (Drug: Toripalimab,
Recruiting
- PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer
- Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)
-
Changchun, Ji Lin, ChinaFirst Hospital of Jilin University
Jul 18, 2022
HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)
Not yet recruiting
- HER2-positive Advanced Gastric Cancer
- HER2-positive Gastroesophageal Junction Adenocarcinoma
- Trastuzumab deruxtecan
- (no location specified)
Aug 11, 2023
Gastric Cancer, GastroEsophageal Cancer Trial in Aurora, Colorado Springs, Highlands Ranch (Pembrolizumab, Olaparib,
Recruiting
- Gastric Cancer
- GastroEsophageal Cancer
- Pembrolizumab
- +2 more
-
Aurora, Colorado
- +2 more
Jan 4, 2023
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) Trial in Tianjin (Serplulimab+Paclitaxel+Apatinib,
Recruiting
- Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Jul 5, 2023
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Houston (Fluorouracil, Leucovorin, Oxaliplatin)
Not yet recruiting
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Fluorouracil
- +4 more
-
Houston, Texas
- +3 more
Nov 13, 2022
Gastric Cancer, Gastroesophageal-junction Cancer Trial in Wuhan, Nanjing, Taiyuan (Tislelizumab, S-1, Oxaliplatin)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Tislelizumab
- +4 more
-
Wuhan, Hubei, China
- +2 more
Jan 16, 2023
Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)
Recruiting
- Gastroesophageal Junction (GEJ) Cancers
- Advanced HNSCC
- N-803
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023
Gastric Cancer Trial in Zhengzhou (Fruquintinib + RC48)
Not yet recruiting
- Gastric Cancer
- Fruquintinib + RC48
-
Zhengzhou, Henan, ChinaThe First Affiliated Hospital of Zhengzhou University
Feb 6, 2022
HER2-positive Gastric Cancer Trial in United States (Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel,
Recruiting
- HER2-positive Gastric Cancer
- Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel
- Cinrebafusp alfa (PRS-343) in combination with tucatinib
-
Santa Barbara, California
- +3 more
Jan 14, 2022
OGT Method Versus the Traditional Overlap Method
Completed
- Gastric Cancer
- The overlap guiding tube(OGT) method
- The conventional overlap method
-
Guangzhou, Guangdong, ChinaNanfang Hospital
Jul 1, 2022
Gastric Cancer Trial in Seoul (pembrolizumab plus ramucirumab)
Recruiting
- Gastric Cancer
- pembrolizumab plus ramucirumab
-
Seoul, Korea, Republic of
- +1 more
Feb 23, 2022
Gastric Cancer, Gastroesophageal-junction Cancer Trial in Gyeonggi-do (Tepotinib plus paclitaxel)
Recruiting
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Tepotinib plus paclitaxel
-
Gyeonggi-do, Korea, Republic ofHallym University Medical Center
Jun 29, 2022